OTCMKTS:DMCAF

DiaMedica Therapeutics Stock Forecast, Price & News

$9.48
-0.36 (-3.66 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.48
Now: $9.48
$9.84
50-Day Range
$0.38
MA: $8.17
$10.25
52-Week Range
$0.38
Now: $9.48
$0.38
Volume139,313 shs
Average Volume131,151 shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.02
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:DMCAF
CUSIPN/A
CIKN/A
Phone763-496-5454
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.49 billion
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.42 out of 5 stars

Medical Sector

1730th out of 2,024 stocks

Pharmaceutical Preparations Industry

704th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$9.48
-0.36 (-3.66 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DMCAF News and Ratings via Email

Sign-up to receive the latest news and ratings for DMCAF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DiaMedica Therapeutics (OTCMKTS:DMCAF) Frequently Asked Questions

What stocks does MarketBeat like better than DiaMedica Therapeutics?

Wall Street analysts have given DiaMedica Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DiaMedica Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Rick Pauls MBA, CEO, Pres & Director (Age 47)
  • Dr. Todd A. Verdoorn Ph.D., Chief Scientific Officer
  • Mr. Scott B. Kellen, CFO & Company Sec. (Age 53)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 69)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 48)

Who are some of DiaMedica Therapeutics' key competitors?

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the OTCMKTS under the ticker symbol "DMCAF."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMCAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMCAF stock can currently be purchased for approximately $9.48.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics has a market capitalization of $1.49 billion.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

Where are DiaMedica Therapeutics' headquarters?

DiaMedica Therapeutics is headquartered at 2 Carlson Parkway Suite 260, Minneapolis MN, 55447.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 Carlson Parkway Suite 260, Minneapolis MN, 55447. The company can be reached via phone at 763-496-5454 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.